Ticagrelor monotherapy within one month of DAPT is non-inferior to continuous DAPT

<p>Adobe Stock</p>
<p>” src=”https://gumlet.assettype.com/healthday%2Fimport%2F28174677%2Forigin.jpg?rect=0%2C0%2C980%2C551&format=auto” srcset=”https://gumlet.assettype.com/healthday %2Fimport%2F28174677%2Forigin.jpg?rect=0%2C0%2C980%2C551&format=auto&w=480 480w, https://gumlet.assettype.com/healthday%2Fimport%2F28174677%2Forigin.jpg?rect=0%2C0% 2C980%2C551&format=auto&w=960 960w, https://gumlet.assettype.com/healthday%2Fimport%2F28174677%2Forigin.jpg?rect=0%2C0%2C980%2C551&format=auto&w=1200 1200w, https://gumlet. assettype.com/healthday%2Fimport%2F28174677%2Forigin.jpg?rect=0%2C0%2C980%2C551&format=auto&w=2048 2048w”/></amp-img></div>
<div class=

FRIDAY, Oct. 27, 2023 (HealthDay News) — Dual antiplatelet therapy (DAPT) is not inferior to discontinuing ticagrelor monotherapy within one month in patients with acute coronary syndrome (ACS), reports say As good as and better than ticagrelor-based 12-month DAPT, a study published online Oct. 25 cycle It coincides with the annual Transcatheter Cardiovascular Therapeutics Conference in San Francisco, October 23-26.

Sung-Jin Hong, MD, of Yonsei University School of Medicine, Seoul, South Korea, and colleagues conducted a randomized, open-label, noninferiority trial involving 2,850 ACS patients who underwent drug-eluting stent implantation at 24 centers in South Korea. At the time of surgery, patients were randomly assigned to receive ticagrelor monotherapy (90 mg twice daily) after less than 1 month of DAPT or 12 months of ticagrelor-based DAPT (1,426 and 1,426 patients, respectively). 1,424 patients).

Researchers found that in the intention-to-treat population, the primary endpoints of net clinical benefit were all-cause death, myocardial infarction, definite or probable stent thrombosis, stroke, and major bleeding one year after the index procedure. The incidence was 2.8% in the group receiving ticagrelor monotherapy after less than 1 month of DAPT and 5.2% in the group receiving 12 months of ticagrelor-based DAPT (hazard ratio, 0.54). The rate of major bleeding was significantly lower in the group receiving ticagrelor monotherapy less than 1 month after DAPT compared with the 12-month DAPT group (1.2% vs 3.4%; hazard ratio, 0.35).

“The significant reduction in major bleeding with ticagrelor monotherapy after less than 1 month in the DAPT arm was a major component of the composite driving these results,” the authors wrote.

Several authors disclosed ties to the biopharmaceutical and medical device industries.

Abstract/Full text

More information

Source link

Leave a Comment